US20180207314A1 - Fascia fibrous compositions and methods for their use and manufacture - Google Patents
Fascia fibrous compositions and methods for their use and manufacture Download PDFInfo
- Publication number
- US20180207314A1 US20180207314A1 US15/876,809 US201815876809A US2018207314A1 US 20180207314 A1 US20180207314 A1 US 20180207314A1 US 201815876809 A US201815876809 A US 201815876809A US 2018207314 A1 US2018207314 A1 US 2018207314A1
- Authority
- US
- United States
- Prior art keywords
- fiber
- human
- fascia
- derived
- thread
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003195 fascia Anatomy 0.000 title claims abstract description 182
- 238000000034 method Methods 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title description 7
- 238000004519 manufacturing process Methods 0.000 title description 5
- 239000000835 fiber Substances 0.000 claims abstract description 358
- 239000000853 adhesive Substances 0.000 claims description 24
- 230000001070 adhesive effect Effects 0.000 claims description 24
- -1 cyanoacrylate ester Chemical class 0.000 claims description 22
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 14
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 7
- 239000002033 PVDF binder Substances 0.000 claims description 7
- 239000004698 Polyethylene Substances 0.000 claims description 7
- 229920000573 polyethylene Polymers 0.000 claims description 7
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 7
- 239000004677 Nylon Substances 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 6
- 239000002729 catgut Substances 0.000 claims description 6
- 229920001778 nylon Polymers 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- 239000004626 polylactic acid Substances 0.000 claims description 6
- 229920001155 polypropylene Polymers 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 abstract description 4
- 210000004872 soft tissue Anatomy 0.000 description 66
- 210000001519 tissue Anatomy 0.000 description 17
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 208000002847 Surgical Wound Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 239000004830 Super Glue Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- 239000012209 synthetic fiber Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920006370 Kynar Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/08—At least partially resorbable materials of animal origin, e.g. catgut, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/105—Polyesters not covered by A61L17/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/12—Homopolymers or copolymers of glycolic acid or lactic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06004—Means for attaching suture to needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00526—Methods of manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00964—Material properties composite
Definitions
- Embodiments of the present invention relate generally to the field of allogeneic transplants, and in particular to allograft compositions containing fascia, fat, or dermis tissue, and methods for their use and manufacture.
- Allograft and autograft tissue are both derived from humans; the difference is that allograft is recovered from an individual (e.g. donor) other than the one (e.g. patient) receiving the graft. Allograft tissue is often taken from cadavers that have donated their bodies so their tissue can be used for living people who are in need of it, for example, patients who are undergoing surgery for various reasons. Such tissues represent a gift from the donor or the donor family to enhance the quality of life for other people.
- Embodiments of the present technology may permit for native, intact, natural, human-derived, or allograft-derived fibers to be used as threads for suturing.
- embodiments may avoid synthetic components, such as synthetic fibers, non-allograft-derived fibers, non-human-derived fibers, or glue, being left in contact with or in a patient.
- Embodiments may allow for reduced, minimal, or no possibility of an immunoresponse related to suture threads. Suture threads disclosed herein may also result in greater utilization of the gifts provided by donors, thereby increasing the value and reach of donations. Greater utilization of intact fibers also may result in economic benefits.
- Embodiments of the present invention encompass techniques for processing fascia fibers or filaments into surgical products, and administering such products to recipient patients.
- Embodiments of the present invention include fascia fibers used for suturing.
- Fascia tissue includes layers of fibrous material within the body that surround muscles and other anatomical features. For example, an abundance of fascia connective tissue can be found at the quadriceps and inner or frontal thigh areas. Typically, fascia is flexible and contains collagen fibers that have been formed by fibroblasts.
- embodiments may include a thread for suturing.
- the thread may include a first portion, which includes a fascia fiber.
- the first portion may have a first end that includes the fascia fiber.
- the thread may also include a second portion including a non-human-derived fiber.
- the second portion may have a first end that includes the non-human-derived fiber. The first end of the second portion may be attached to the first end of the first portion.
- embodiments may include a method of forming a thread.
- the method may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber.
- the method may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.
- embodiments may include a method of suturing.
- the method may include inserting a thread into a soft tissue.
- the thread may include a first portion that includes a fascia fiber and a second portion that includes a non-human-derived fiber. Inserting the thread into the soft tissue may include inserting the second portion into the soft tissue before the first portion.
- the method may also include removing the second portion from the first portion when the first portion is in contact with the soft tissue.
- FIGS. 1A, 1B, and 1C show threads according to embodiments of the present invention.
- FIG. 2 shows a method of forming a thread according to embodiments of the present invention.
- FIGS. 3A, 3B, and 3C show different attachment configurations according to embodiments of the present invention.
- FIG. 4 shows a method of suturing according to embodiments of the present invention.
- FIGS. 5A and 5B are simplified illustrations of suturing according to embodiments of the present invention.
- FIG. 6 is a photo of a thread according to embodiments of the present invention.
- Embodiments of the present invention include threads for suturing, and methods of forming and using the threads.
- the threads may include a human-derived fiber portion and a non-human-derived portion.
- Human-derived fibers may also be referred to as natural or native fibers.
- Human-derived fibers may include allograft-derived fibers and may specifically include fascia fibers.
- non-human-derived may refer to fibers or other material that may not be native to a donor or a subject of suturing.
- Non-human-derived fibers may also be referred to as synthetic fibers or non-native fibers. For example, if a human patient is to be sutured, a fiber such as silk may be considered synthetic.
- a donor fascia fiber portion with one or more non-human-derived portions may allow for greater utilization of donor fascia fibers and a lower likelihood of an untoward immunoresponse when the thread is placed in a recipient or patient.
- the decreased likelihood of an immune-related rejection response is at least partly because of the absence of donor-derived blood elements.
- These potentially immunogenic ingredients may be removed by the methods described herein, which then render the fibers acellular and non-immunogenic.
- Embodiments of the present technology also may benefit from clinical and therapeutic advantages of using fascia fiber for suturing since the fascia fiber as a human-derived collagenous material is biocompatible with human recipient tissue and unlikely to provoke a biological foreign body response.
- Non-human-derived threads Conventional techniques of suturing have drawbacks. Such methods presently use only non-human-derived threads. Using only non-human-derived threads introduces a non-native, normally foreign component to the patient's body. In some cases, non-human-derived threads may induce an immunoresponse or a hypoallergenic response. Non-human-derived threads also may not degrade or be remodeled in the body and may need to be removed, which may require an additional procedure.
- Native fibers such as fascia fibers obtained from a human donor, can have their own problems when substituted for non-human-derived fibers in conventional techniques.
- the length of fascia fibers that can be used for suturing may be limited by the length of the fascia fiber obtained from the donor body. In many cases, this length may be too short to securely suture a wound or surgical incision of a patient.
- the fascia fibers cannot be easily lengthened by attaching fascia fibers to other fascia fibers, with such attachments often resulting in a thread with lower strength. For example, when combining multiple fascia fibers to make the fascia portion longer without adding a binder, the fibers slide off each other once wet with forces of less than 1 lb.
- a weave of multiple fibers has less overall strength than a straight fascia fiber.
- long fascia fibers may not be uniform in thickness and in strength across the entire length of the fiber, and as a result, shorter fascia fibers may be used to maintain a minimum uniformity and strength. Even if a fascia fiber was long enough and uniform enough for a suture, suturing may often result in cutting off and discarding excess donor fascia fiber. Wasting fascia fiber is not economical and also does not properly honor the gift provided by a donor. Additionally, medical professionals, including surgeons, may be accustomed to non-human-derived fibers for suturing. Using only a fascia fiber, even if long enough for a suture, may have a different feel and resistance than a non-human-derived fiber.
- the fascia may refer to a fibrous membrane which covers most major muscles, nerves, and organs.
- Embodiments of the present invention encompass cadaveric fascia graft compositions, and methods for their use and manufacture.
- fascia tissue can provide a biologically-derived fibrous source of collagen that can be further manufactured or processed into predetermined various configurations, such as fascia fiber, fascia collagen bundles, fascia wires, fascia sheets, fascia filaments, and the like.
- Embodiments may include a thread for suturing.
- the thread may include a fascia fiber attached at both ends to two non-human-derived fibers.
- the thread may have a strength that allows the thread to be used a surgical suture.
- a thread with a diameter of about 200 to 300 microns may have a strength to withstand about 5 to 7 lbs of force on average.
- FIG. 1A shows an example of a thread 100 .
- Thread 100 includes a first portion 102 that includes a fascia fiber.
- First portion 102 may have a first end 104 that includes the fascia fiber.
- First portion 102 may have a second end 106 that includes the fascia fiber. The first end and the second end may be on opposite ends of the first portion.
- first end 104 and the second end 106 may include the circular or near-circular sections of the cylinder.
- first end 104 and second end 106 may include the surfaces at the limits of first portion 102 in either axial direction.
- the axial direction is illustrated by line 108 .
- the radial direction is depicted by line 110 .
- FIG. 1B shows a circular cross section of the thread at dashed line 112 .
- the cross section in FIG. 1B is of first portion 102 , but other portions of thread 100 may also have a circular cross section. In some instances or areas, the thread may not be perfectly circular.
- the radius of the thread may differ by a maximum of 5%, 10%, or 15% from the average radius.
- the fascia fiber may be recovered from a single cadaveric donor.
- the fascia fiber may include a plurality of individual fascia fiber filaments. Each fascia fiber filament may have a diameter as low as 5 ⁇ m with a length of 7 to 10 inches.
- Fascia fibers may be any fibers described in U.S. Patent Application No. 61/779,269 filed Mar. 13, 2013 or Ser. No. 14/204,346 filed Mar. 11, 2014, the contents of which are incorporated herein by reference for all purposes.
- human-derived fiber may include fibers made from ligaments, tendons, or bones.
- Thread 100 may also include a second portion 109 that includes a first non-human-derived fiber.
- Second portion 109 may have a first end 114 that includes the first synthetic fiber.
- the first non-human-derived fiber may include nylon, polyester, polyethylene, polyglycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, or silk. If the first non-human-derived fiber is cylindrical or near-cylindrical in shape, first end 114 may include a circular section of the first non-human-derived fiber. In other words, first end 114 may include the surface at the limit of second portion 109 in an axial direction. First end 114 of second portion 109 may be attached to first end 104 of first portion 102 .
- First end 114 of second portion 109 may be attached to first end 104 of first portion 102 by an adhesive, which may include cyanoacrylate or a cyanoacrylate ester.
- the adhesive may include Dermabond® or Super Glue®.
- second portion 109 may be melted onto first portion 102 .
- second portion 109 may be stapled onto first portion 102 .
- First end 114 of second portion 109 may be attached to first end 104 of first portion 102 directly at the end surface of each portion.
- first end 114 of second portion 109 may be attached to first end 104 of first portion 102 because second portion 109 and first portion 102 overlap in the axial direction and the two portions are attached in the overlap.
- Thread 116 may include thread 100 from FIG. 1A and may further include a third portion 118 that includes a second non-human-derived fiber.
- Third portion 118 may have a first end 120 that includes the second non-human-derived fiber.
- First end 120 of third portion 118 may be similar to first end 114 of second portion 109 .
- First end 120 may include a circular area of a cylindrical or near-cylindrical third portion 118 .
- first end 120 may include a surface at the limit of third portion 118 in the axial direction.
- First end 120 of third portion 118 may be attached to second end 106 of first portion 102 .
- First end 120 of third portion 118 may be attached to second end 106 of first portion 102 by an adhesive, including any adhesive disclosed herein.
- the orientation of the attachment may be the same as any way the second portion 109 could be attached to first portion 102 .
- the first non-human-derived fiber may be the same type of fiber as the second non-human-derived fiber. In other embodiments, the first non-human-derived fiber may be different from the second non-human-derived fiber.
- the second non-human-derived fiber may be added to provide a longer length to the thread.
- the thread may be used for orthoscopic applications. The thread may often involve tying knots on the outside of the wound or the human body, and a longer thread may allow for knots to be more easily tied and manipulated.
- Thread 116 may have 4 to 8 lbs of ultimate tensile strength.
- the strength of the thread may be limited by the fascia fiber and may be related to the diameter of the fascia fiber. When force is applied, the thread may break at the fascia fiber and not the junction of the fascia fiber with the non-human-derived fiber. In other words, the adhesive may have a higher ultimate tensile strength than the fascia fiber.
- Second portion 109 of thread 100 may contact a piercing element 122 .
- Piercing element 122 may be a surgical needle, other needle, or any suitable device. Second portion 109 may be fastened to piercing element 122 . In embodiments, one end of piercing element 122 may be crimped onto second portion 109 , an adhesive may attach piercing element 122 to second portion 109 , second portion 109 may be tied onto piercing element 122 , or second portion 109 may be attached to piercing element 122 by other fastening means. Piercing element 122 may not be considered part of thread 100 .
- Thread 116 may have a length based on the intended medical or surgical procedure.
- the thread may be long enough so that a knot may be tied, and a medical professional may not need to use magnifying glasses tie the knot.
- the total length of thread 116 may be from 18 inches to 54 inches, 15 inches to 18 inches, 18 inches to 24 inches, 24 inches to 30 inches, 30 inches to 36 inches, 36 inches to 40 inches, 40 inches to 48 inches, 48 inches to 54 inches, over 48 inches, or any combination of ranges according to embodiments.
- the total length of thread 116 does not include piercing element 122 .
- First portion 102 may have a length from 6 inches to 8 inches, from 8 inches to 10 inches, from 10 inches to 12 inches, from 12 inches to 18 inches, over 18 inches, or any combination of ranges according to embodiments.
- First portion 102 may have a diameter from 300 ⁇ m to 400 ⁇ m, 250 ⁇ m to 300 ⁇ m, 300 ⁇ m to 350 ⁇ m, 350 ⁇ m to 400 ⁇ m, 400 ⁇ m to 450 ⁇ m, over 450 ⁇ m, or any combination of ranges according to embodiments.
- Thread 100 may have a maximum diameter that does not exceed the diameter of the first portion by greater than 10 ⁇ m, 20 ⁇ m, 30 ⁇ m, 40 ⁇ m, 50 ⁇ m, or 60 ⁇ m in embodiments. The maximum diameter of the thread may be where the first portion attaches to the second portion of third portion.
- Second portion 109 may have a length from 6 inches to 8 inches, from 8 inches to 10 inches, from 10 inches to 12 inches, from 12 inches to 18 inches, 18 inches to 24 inches, over 24 inches, or any combination of ranges according to embodiments. Because second portion 109 may be non-human-derived fiber, second portion 109 may not be limited in length, and the length may be based on commercially available fibers. The length of third portion 118 may be equal to, within 5% of, within 10% of, or within 20% of the length of second portion 109 .
- embodiments may include a method 200 of forming a thread.
- the thread may be any thread described herein.
- Method 200 may include obtaining and forming the fascia fiber.
- a fascia fiber may be obtained according to U.S. Patent Application U.S. Patent Application No. 61/779,269 filed Mar. 13, 2013 or Ser. No. 14/204,346 filed Mar. 11, 2015, the contents of which are incorporated herein by reference for all purposes.
- a method of obtaining a fascia fiber may include obtaining a deceased donor fascia tissue, treating the deceased donor fascia tissue with acetone, and obtaining one or more intact fascia fibers from the treated deceased donor fascia tissue.
- An intact fascia fiber may have a diameter within a range from 5 to 200 microns. In some cases, an intact fascia fiber may have a length greater than 20 cm.
- the intact fascia fiber may be used directly as a fascia fiber, or the intact fascia fiber may be further processed (e.g. cut into two or more pieces) to produce a fascia fiber.
- method 200 may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber. Attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber may include directly binding the section at the limit of the fascia fiber in the axial direction with the section at the limit of the first non-human-derived fiber in the axial direction.
- FIG. 3A shows an axial cross sectional view of fascia fiber 302 attached to non-human-derived fiber 304 .
- non-human-derived fiber 304 may have a large diameter than fascia fiber 302 across the whole of non-human-derived fiber 304 , or non-human-derived fiber 304 may have a larger diameter at only end 306 .
- method 200 may include tapering the fascia fiber to form the first end of the fascia fiber before attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber.
- FIG. 3B shows an axial cross sectional view of fascia fiber 308 and non-human-derived fiber 310 . Tapering is shown in area 312 . Fascia fiber 308 may be tapered at one end and from one side. Independently, non-human-derived fiber 310 may be tapered at one end and from one side. In embodiments, non-human-derived fiber 310 may not be tapered while fascia fiber may be tapered. Non-human-derived fiber 310 may be a woven fiber, which may be more difficult to taper.
- the tapered ends decrease the thickness of the fibers and may reduce the diameter or reduce the diameter of the thread at the junction. Avoiding increasing the diameter of the thread at the junction may be desirable for surgical applications. A smaller diameter at the junction avoids unnecessarily enlarging suture points in a patient, which may then result in faster recovery times.
- the first end of the fascia fiber may be attached to the first end of the first non-human-derived fiber by any adhesive described herein.
- method 200 may include a tubular component that may bind the fascia fiber to the non-human-derived fiber.
- the ends of the fibers may be inserted into the tubular component, which may be a tube, cylinder, or other similar shape.
- FIG. 3C shows an axial cross sectional view of fascia fiber 314 and non-human-derived fiber 316 .
- One end of fascia fiber 314 and one end of non-human-derived fiber 316 may be inserted into tube 318 .
- Tube 318 may be reduced in size to bind the two fibers together. Before reduction in size, tube 318 may be 0.5 inches to 2 inches long, including 0.5 inches to 1 inch, 1 inch to 1.5 inches, or 1.5 inches to 2 inches.
- the inner diameter of tube 318 before reduction in size may be slightly larger than the diameter of the fascia fiber or the non-human-derived fiber.
- the thickness of the wall of tube 318 may be from 100 ⁇ m to 600 ⁇ m.
- the microtube may include tubing made of acrylated olefins, polyvinylidene fluoride (e.g, Kynar®), polyvinylchloride, cellulose, polyolefins (e.g., Neoprene), polytetrafluoroethylene (e.g., Teflon®), fluoropolymer elastomer (e.g., Viton®), or other suitable material.
- tube 318 may be heated, which may cause tube 318 to shrink and bind the fibers together.
- tube 318 may be a material, such as those previously listed, that shrinks under application of heat. These materials are sometimes known as heat shrink tubing.
- Heat may be applied to the tubular component by conduction, convection, or radiation.
- a heat gun, heat fan (e.g., a device resembling a hair dryer), iron, heated surface, or other suitable device may be used to shrink the tubular material.
- Another method to reduce the size of tube 318 may be the application of a chemical that causes tube 318 to shrink.
- cellulose tubing may shrink after water is applied.
- Adhesive may be excluded to avoid difficulties or inefficiencies in applying to small fibers. However, applying an adhesive to attach fibers may be faster than using a tubular component, which requires inserting the fibers into a tubular component and then heating or otherwise treating the tubular component.
- adhesive may be used in combination with the tubular component to additionally increase binding strength.
- an adhesive may first be applied to two ends of fibers, and the tube may be shrunk on top of the two ends.
- adhesive may be applied to the inner surface of the tube, and heat may be applied to shrink the tube and/or cure the adhesive.
- the fascia fibers may be tapered before inserting the fascia fiber and non-human-derived fiber into a tubular component.
- method 200 may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.
- Method 200 may include tapering the fascia fiber to form the second end of the fascia fiber before attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber. Attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber may be in a manner similar to any described herein for the attaching of the first end of the fascia fiber to the first end of the first non-human-derived fiber.
- method 200 may include determining the length of at least one of the first non-human-derived fiber or the second non-human-derived fiber.
- the length of the non-human-derived fibers may be a length based on the preference of the medical professional (e.g. a surgeon who is applying thread to a patient) or a length suitable to allow the thread to be tied off.
- embodiments may include a method 400 of suturing.
- Suturing may be used to close a wound or a surgical incision in a tissue of a human or animal subject.
- method 400 may include inserting a thread into a soft tissue.
- the soft tissue may include the skin of a human patient.
- the thread may include a first portion including a fascia fiber and a second portion including a non-human-derived fiber.
- the first portion may include any portion of the fascia fiber described herein, and the second portion may be any portion of the non-human-derived fiber described herein.
- Inserting the thread into the soft tissue may include inserting the second portion into the soft tissue before the first portion. Inserting the non-human-derived fiber may provide the medical professional similar tactile feedback and resistance as with conventional non-human-derived fibers for suturing.
- the second portion may be in contact with a piercing element.
- Method 400 may include attaching the second portion to the piercing element, and method 400 may include inserting the piercing element into the soft tissue before inserting the thread into the soft tissue.
- Method 400 may include a thread that includes a third portion comprising a second non-human-derived fiber.
- the third portion may be any portion of the second non-human-derived fiber described herein.
- the first portion may be attached to the second portion, and the first portion may be attached to the third portion. Inserting the thread into the soft tissue, as in block 402 , may exclude inserting the third portion into the soft tissue.
- method 400 may include removing the second portion from the first portion when the first portion is in contact with the soft tissue.
- Method 400 may also include removing the third portion from the first portion when the first portion is in contact with the soft tissue. Removing the second portion or the third portion may be by using scissors or a knife edge. Removing the portions may include removing adhesive used to attach either portion to the first portion of fascia fiber.
- method 400 may include fastening the first portion to the soft tissue.
- fastening the first portion to the soft tissue may occur before removing the second portion from the first portion.
- Method 400 may include tying the first portion in a surgical knot to fasten the first portion to the soft tissue. Tying the first portion may include closing a wound or a surgical incision.
- the soft tissue may not have an immunoresponse to the first portion.
- the first portion may be hypoallergenic
- FIG. 5A is a simplified illustration of suturing.
- a soft tissue 502 and a soft tissue 504 are shown as being at least partially separated by some space or otherwise as being at least partially unconnected from one another.
- Soft tissue 502 and soft tissue 504 may be human dermal layers and may be separated by an incision, such as by a scalpel or other cutting instrument. In some examples, soft tissue 502 and soft tissue 504 may have been separated as a result of some unintended trauma to the soft tissue.
- Soft tissue 502 and soft tissue 504 may be connected to a common section (not shown) of soft tissue.
- the thread used to suture soft tissue 502 and soft tissue 504 together may include a portion 506 of native fiber, such as fascia fiber.
- Portion 506 may be attached at one end to a first portion 508 of non-human-derived fiber and attached at the other end to a second portion 510 of non-human-derived fiber.
- First portion 508 of non-human-derived fiber may be attached to needle 512 or any other piercing element.
- the attachment of first portion 508 to needle 512 may be by a fastening device, or first portion 508 may be threaded through needle 512 .
- Portion 506 may be any portion of fascia fiber described herein.
- First portion 508 of non-human-derived fiber and second portion 510 of non-human-derived fiber may be any portion of non-human-derived fiber described herein.
- Needle 512 may pierce through soft tissue 502 and soft tissue 504 several times, drawing the thread with needle 512 .
- FIG. 5A sections of portion 506 of native fiber that are behind either soft tissue 502 or soft tissue 504 are depicted as dashed lines.
- Suturing may include alternating piercing of soft tissue 502 and soft tissue 504 .
- First portion 508 is completely pulled through either or both of soft tissue 502 or soft tissue 504 .
- Second portion 510 may not enter either or both of soft tissue 502 or soft tissue 504 .
- second portion 510 may not a cross section with its circumference surrounded by soft tissue. Second portion 510 may not contact soft tissue or may contact soft tissue only on the planar or near-planar surface of the soft tissue.
- the thread may be manipulated such that portion 506 pulls soft tissue 502 and soft tissue 504 together.
- the effect of bringing soft tissue 502 and soft tissue 504 may be to close a wound or a surgical incision.
- Portion 506 of native fiber of the thread may be tied off using a surgical knot or any suitable suturing technique.
- First portion 508 of non-human-derived fiber and second portion 510 of non-human-derived fiber may be removed from the native fiber. Removal may be by scissors, a razor, a knife-edge, or by an applied force (e.g., pulling thread apart at the attached connection). In some cases, removal of the non-human-derived fiber may also include removal of a section of the native fiber.
- FIG. 5B illustrates a possible configuration after removal of first portion 508 and second portion 510 .
- Soft tissue 502 and soft tissue 504 are in contact.
- Portion 506 of native fiber may provide a force to maintain contact between the two soft tissues. Areas where portion 506 are behind the soft tissue are illustrated as dashed lines. Because the native fiber is completely natural, the likelihood of the soft tissue suffering an immunoresponse is low.
- Human-derived fibers may be absorbed or remodeled (i.e., bio-resorbed and replaced by the patient's own tissue) in the human body.
- FIG. 6 is a photo of an example thread.
- Uncoiled portion 602 is fascia fiber, and coiled portion 604 is non-human-derived fiber.
- the fascia fiber is 12 to 18 inches long, and the non-human-derived fiber is 18 inches long.
- the non-human-derived fibers is Teleflex® Force Fiber® #2, which is a polyethylene fiber.
- fascia fibers 12 to 18 inches long are obtained.
- the fascia fibers are tapered at both ends to reduce the diameter of the fiber at the end.
- Each of the fascia fibers are separately attached at one end to one end of a non-human-derived fiber of nylon, polyester, polyethylene, polygycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, or silk to form 9 separate threads.
- the non-human-derived fiber is about 18 inches long.
- the fascia fibers are attached to the non-human-derived fiber by cyanoacrylate adhesive.
- Each of the fascia fibers at the other end is then attached to the same type of non-human-derived fiber to form 9 separate threads with fascia fiber attached at both ends to separate non-human-derived fibers of the same type.
- the second non-human-derived fiber is about 18 inches long.
- the fascia fiber is attached to the second non-human-derived fiber by cyanoacrylate adhesive.
- fascia fibers 12 to 18 inches long are obtained.
- One end of each fascia fibers is inserted into a separate tube about 1 inch in length.
- One end of a non-human-derived fiber of nylon, polyester, polyethylene, polygycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, and silk is each inserted into a separate tube.
- the separate tubes have an inner diameter slightly larger than the diameter of the fascia fiber and the non-human-derived fiber.
- the tube is heated to shrink the tube to bind the fascia fiber with the non-human-derived fiber.
- the non-human-derived fiber is about 18 inches long.
- the process of binding the fascia fiber with the non-human-derived fiber with a tube is repeated with the other end of the fascia fiber to a second non-human-derived fiber of the same type.
- the second non-human-derived fiber is about 18 inches long.
- Example 3 is repeated except that the fascia fibers are tapered at both ends before the fibers are inserted into the tube.
- Example 3 is repeated except that the fascia fibers are attached to the non-human-derived fibers with cyanoacrylate before shrinking the tube with applied heat.
- Example 4 is repeated except that the fascia fibers are attached to the non-human-derived fibers with cyanoacrylate before shrinking the tube with applied heat.
- Each of the threads of Examples 3, 4, 5, and 6 is attached to a surgical needle. Each thread is used for suturing. A knot is tied in each thread to close a wound or surgical incision in a patient. The non-human-derived fibers are then cut off the thread, leaving only fascia fiber in contact with the patient.
- embodiments may include a thread for suturing.
- the thread may include a first portion that includes a fascia fiber.
- the first portion may have a first end that includes the fascia fiber.
- the thread may also include a second portion that includes a non-human-derived fiber.
- the second portion may have a first end that includes the non-human-derived fiber. The first end of the second portion may be attached to the first end of the first portion.
- the non-human-derived fiber may be a first non-human-derived fiber.
- the thread may further include a third portion that includes a second non-human-derived fiber.
- the first portion may have a second end that includes the fascia fiber.
- the third portion may have a first end that includes the second non-human-derived fiber.
- the first end of the third portion may be attached to the second end of the first portion.
- the first non-human-derived fiber and the second non-human-derived fiber may be the same type of fiber.
- the thread may have a total length from 36 inches to 54 inches.
- the first portion may have a length from 12 inches to 18 inches.
- the second portion may have a length from 12 inches to 18 inches.
- the first end of the second portion may be attached to the first end of the first portion by an adhesive.
- the adhesive may include a cyanoacrylate or a cyanoacrylate ester.
- the thread may have a strength that allows the thread to be used as a surgical suture.
- the first portion may have a diameter from 300 ⁇ m to 400 ⁇ m.
- the thread may have a maximum diameter that does not exceed the diameter of the first portion by greater than 50 ⁇ m.
- the thread may further include a piercing element in contact with the second portion.
- the piercing element may be a surgical needle.
- the fascia fiber may be obtained from a single cadaveric donor.
- the non-human-derived fiber may include nylon, polyester, polyethylene, polyglycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, or silk.
- embodiments may include methods of forming a thread.
- the methods may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber.
- the methods may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.
- methods may include tapering the fascia fiber to form the first end of the fascia fiber before attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber. Methods may also include tapering the fascia fiber to form the second end of the fascia fiber before attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber.
- attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber may include applying an adhesive to at least one of the first end of the fascia fiber or the first end of the first non-human-derived fiber, and attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber comprises applying the adhesive to at least one of the second end of the fascia fiber or the first end of the second non-human-derived fiber.
- the adhesive may include a cyanoacrylate or a cyanoacrylate ester.
- attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber may include inserting the first end of the fascia fiber into a first end of a first tubular component, inserting the first end of the first non-human-derived fiber into a second end of the first tubular component, where the second end is on an opposite end of the first tubular component as the first end of the first tubular component, and reducing an inner diameter of the first tubular component.
- attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber may include inserting the second end of the fascia fiber into a first end of a second tubular component, inserting the first end of the second non-human-derived fiber into a second end of the second tubular component, where the second end is on an opposite end of the second tubular component as the first end of the second tubular component, and reducing an inner diameter of the second tubular component.
- Reducing the inner diameter of the first tubular component may include heating the first tubular component. In some embodiments, reducing the inner diameter of the first tubular component comprises applying water to the first tubular component.
- Methods may include forming the fascia fiber.
- the fascia fiber may be obtained from a single cadaveric donor.
- Embodiments may include attaching a second end of the first non-human-derived fiber to a piercing element.
- methods may include attaching a second end of the second non-human-derived fiber to a piercing element.
- the piercing element may be a surgical needle.
- the first non-human-derived fiber and the second non-human-derived fiber may be the same type of fiber.
- the thread may have a total length from 36 inches to 54 inches.
- the fascia fiber may have a length from 12 inches to 18 inches.
- the first non-human-derived fiber may have a length from 12 inches to 18 inches.
- the second non-human-derived fiber may have a length from 12 inches to 18 inches.
- the fascia fiber may have a diameter from 300 ⁇ m to 400 ⁇ m.
- the thread may have a maximum diameter that does not exceed the diameter of the fascia fiber by greater than 50 ⁇ m.
- the first non-human-derived fiber or the second non-human-derived fiber may include nylon, polyester, polyethylene, polyglycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, or silk.
- the thread formed may be any embodiment of a thread described herein.
- embodiments may include methods of suturing.
- the methods may include inserting a thread into a soft tissue.
- the thread may include a first portion that includes a fascia fiber and a second portion that includes a non-human-derived fiber. Inserting the thread into the soft tissue may include inserting the second portion into the soft tissue before the first portion.
- the methods may further include removing the second portion from the first portion when the first portion is in contact with the soft tissue.
- the methods may include a thread that includes a third portion of a second non-human-derived fiber.
- the first portion may be attached to the second portion, and the first portion may be attached to the third portion. Inserting the thread into the soft tissue may not include inserting the third portion into the soft tissue.
- the methods may further include removing the third portion from the first portion when the first portion is in contact with the soft tissue.
- the soft tissue may be skin of a human patient.
- the second portion of the thread may be in contact with a piercing element.
- Methods may also include inserting the piercing element into the soft tissue before inserting the thread into the soft tissue.
- Methods may include fastening the first portion to the soft tissue.
- Embodiments may include tying the first portion to fasten the first portion to the soft tissue. Tying the first portion may include closing a wound or a surgical incision.
- the soft tissue may not have an immunoresponse to the first portion.
- the thread may be any thread described herein.
Abstract
Description
- This application claims the benefit of priority to U.S. Provisional Application No. 62/450,957, filed Jan. 26, 2017, the entire contents of which are incorporated herein by reference for all purposes.
- Embodiments of the present invention relate generally to the field of allogeneic transplants, and in particular to allograft compositions containing fascia, fat, or dermis tissue, and methods for their use and manufacture.
- Human tissue compositions, which may be derived from cadaveric donors, have been used for many years in various surgical procedures. Allograft and autograft tissue are both derived from humans; the difference is that allograft is recovered from an individual (e.g. donor) other than the one (e.g. patient) receiving the graft. Allograft tissue is often taken from cadavers that have donated their bodies so their tissue can be used for living people who are in need of it, for example, patients who are undergoing surgery for various reasons. Such tissues represent a gift from the donor or the donor family to enhance the quality of life for other people.
- Although human tissue compositions and methods are presently available and provide real benefits to patients in need thereof, many advances may still be made to provide improved compositions and methods for for their use and manufacture. The fibrous fascia compositions and treatment and manufacture methods described herein provide further solutions and answers to at least some of these outstanding needs.
- Embodiments of the present technology may permit for native, intact, natural, human-derived, or allograft-derived fibers to be used as threads for suturing. In addition, embodiments may avoid synthetic components, such as synthetic fibers, non-allograft-derived fibers, non-human-derived fibers, or glue, being left in contact with or in a patient. Embodiments may allow for reduced, minimal, or no possibility of an immunoresponse related to suture threads. Suture threads disclosed herein may also result in greater utilization of the gifts provided by donors, thereby increasing the value and reach of donations. Greater utilization of intact fibers also may result in economic benefits. Embodiments of the present invention encompass techniques for processing fascia fibers or filaments into surgical products, and administering such products to recipient patients. Embodiments of the present invention include fascia fibers used for suturing.
- Fascia tissue includes layers of fibrous material within the body that surround muscles and other anatomical features. For example, an abundance of fascia connective tissue can be found at the quadriceps and inner or frontal thigh areas. Typically, fascia is flexible and contains collagen fibers that have been formed by fibroblasts.
- In a first aspect, embodiments may include a thread for suturing. The thread may include a first portion, which includes a fascia fiber. The first portion may have a first end that includes the fascia fiber. The thread may also include a second portion including a non-human-derived fiber. The second portion may have a first end that includes the non-human-derived fiber. The first end of the second portion may be attached to the first end of the first portion.
- In a second aspect, embodiments may include a method of forming a thread. The method may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber. The method may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.
- In a third aspect, embodiments may include a method of suturing. The method may include inserting a thread into a soft tissue. The thread may include a first portion that includes a fascia fiber and a second portion that includes a non-human-derived fiber. Inserting the thread into the soft tissue may include inserting the second portion into the soft tissue before the first portion. The method may also include removing the second portion from the first portion when the first portion is in contact with the soft tissue.
-
FIGS. 1A, 1B, and 1C show threads according to embodiments of the present invention. -
FIG. 2 shows a method of forming a thread according to embodiments of the present invention. -
FIGS. 3A, 3B, and 3C show different attachment configurations according to embodiments of the present invention. -
FIG. 4 shows a method of suturing according to embodiments of the present invention. -
FIGS. 5A and 5B are simplified illustrations of suturing according to embodiments of the present invention. -
FIG. 6 is a photo of a thread according to embodiments of the present invention. - Embodiments of the present invention include threads for suturing, and methods of forming and using the threads. The threads may include a human-derived fiber portion and a non-human-derived portion. Human-derived fibers may also be referred to as natural or native fibers. Human-derived fibers may include allograft-derived fibers and may specifically include fascia fibers. In this application, non-human-derived may refer to fibers or other material that may not be native to a donor or a subject of suturing. Non-human-derived fibers may also be referred to as synthetic fibers or non-native fibers. For example, if a human patient is to be sutured, a fiber such as silk may be considered synthetic. The combination of a donor fascia fiber portion with one or more non-human-derived portions may allow for greater utilization of donor fascia fibers and a lower likelihood of an untoward immunoresponse when the thread is placed in a recipient or patient. The decreased likelihood of an immune-related rejection response is at least partly because of the absence of donor-derived blood elements. These potentially immunogenic ingredients may be removed by the methods described herein, which then render the fibers acellular and non-immunogenic. Embodiments of the present technology also may benefit from clinical and therapeutic advantages of using fascia fiber for suturing since the fascia fiber as a human-derived collagenous material is biocompatible with human recipient tissue and unlikely to provoke a biological foreign body response.
- Conventional techniques of suturing have drawbacks. Such methods presently use only non-human-derived threads. Using only non-human-derived threads introduces a non-native, normally foreign component to the patient's body. In some cases, non-human-derived threads may induce an immunoresponse or a hypoallergenic response. Non-human-derived threads also may not degrade or be remodeled in the body and may need to be removed, which may require an additional procedure.
- Native fibers, such as fascia fibers obtained from a human donor, can have their own problems when substituted for non-human-derived fibers in conventional techniques. The length of fascia fibers that can be used for suturing may be limited by the length of the fascia fiber obtained from the donor body. In many cases, this length may be too short to securely suture a wound or surgical incision of a patient. The fascia fibers cannot be easily lengthened by attaching fascia fibers to other fascia fibers, with such attachments often resulting in a thread with lower strength. For example, when combining multiple fascia fibers to make the fascia portion longer without adding a binder, the fibers slide off each other once wet with forces of less than 1 lb. In addition, for a given diameter, a weave of multiple fibers has less overall strength than a straight fascia fiber. Moreover, long fascia fibers may not be uniform in thickness and in strength across the entire length of the fiber, and as a result, shorter fascia fibers may be used to maintain a minimum uniformity and strength. Even if a fascia fiber was long enough and uniform enough for a suture, suturing may often result in cutting off and discarding excess donor fascia fiber. Wasting fascia fiber is not economical and also does not properly honor the gift provided by a donor. Additionally, medical professionals, including surgeons, may be accustomed to non-human-derived fibers for suturing. Using only a fascia fiber, even if long enough for a suture, may have a different feel and resistance than a non-human-derived fiber.
- The fascia may refer to a fibrous membrane which covers most major muscles, nerves, and organs. Embodiments of the present invention encompass cadaveric fascia graft compositions, and methods for their use and manufacture. For example, fascia tissue can provide a biologically-derived fibrous source of collagen that can be further manufactured or processed into predetermined various configurations, such as fascia fiber, fascia collagen bundles, fascia wires, fascia sheets, fascia filaments, and the like.
- Embodiments may include a thread for suturing. The thread may include a fascia fiber attached at both ends to two non-human-derived fibers. The thread may have a strength that allows the thread to be used a surgical suture. A thread with a diameter of about 200 to 300 microns may have a strength to withstand about 5 to 7 lbs of force on average.
FIG. 1A shows an example of athread 100.Thread 100 includes afirst portion 102 that includes a fascia fiber.First portion 102 may have afirst end 104 that includes the fascia fiber.First portion 102 may have asecond end 106 that includes the fascia fiber. The first end and the second end may be on opposite ends of the first portion. If the fascia fiber can be considered a cylinder or a solid similar to a cylinder,first end 104 and thesecond end 106 may include the circular or near-circular sections of the cylinder. In other words,first end 104 andsecond end 106 may include the surfaces at the limits offirst portion 102 in either axial direction. The axial direction is illustrated byline 108. The radial direction is depicted byline 110.FIG. 1B shows a circular cross section of the thread at dashedline 112. The cross section inFIG. 1B is offirst portion 102, but other portions ofthread 100 may also have a circular cross section. In some instances or areas, the thread may not be perfectly circular. The radius of the thread may differ by a maximum of 5%, 10%, or 15% from the average radius. The fascia fiber may be recovered from a single cadaveric donor. The fascia fiber may include a plurality of individual fascia fiber filaments. Each fascia fiber filament may have a diameter as low as 5 μm with a length of 7 to 10 inches. Fascia fibers may be any fibers described in U.S. Patent Application No. 61/779,269 filed Mar. 13, 2013 or Ser. No. 14/204,346 filed Mar. 11, 2014, the contents of which are incorporated herein by reference for all purposes. In addition to fascia fiber, human-derived fiber may include fibers made from ligaments, tendons, or bones. -
Thread 100 may also include asecond portion 109 that includes a first non-human-derived fiber.Second portion 109 may have afirst end 114 that includes the first synthetic fiber. The first non-human-derived fiber may include nylon, polyester, polyethylene, polyglycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, or silk. If the first non-human-derived fiber is cylindrical or near-cylindrical in shape,first end 114 may include a circular section of the first non-human-derived fiber. In other words,first end 114 may include the surface at the limit ofsecond portion 109 in an axial direction.First end 114 ofsecond portion 109 may be attached tofirst end 104 offirst portion 102.First end 114 ofsecond portion 109 may be attached tofirst end 104 offirst portion 102 by an adhesive, which may include cyanoacrylate or a cyanoacrylate ester. The adhesive may include Dermabond® or Super Glue®. In some embodiments,second portion 109 may be melted ontofirst portion 102. In other embodimentssecond portion 109 may be stapled ontofirst portion 102.First end 114 ofsecond portion 109 may be attached tofirst end 104 offirst portion 102 directly at the end surface of each portion. In other embodiments,first end 114 ofsecond portion 109 may be attached tofirst end 104 offirst portion 102 becausesecond portion 109 andfirst portion 102 overlap in the axial direction and the two portions are attached in the overlap. - Some embodiments may include
thread 116 shown inFIG. 1C .Thread 116 may includethread 100 fromFIG. 1A and may further include athird portion 118 that includes a second non-human-derived fiber.Third portion 118 may have afirst end 120 that includes the second non-human-derived fiber.First end 120 ofthird portion 118 may be similar tofirst end 114 ofsecond portion 109.First end 120 may include a circular area of a cylindrical or near-cylindricalthird portion 118. In some examples,first end 120 may include a surface at the limit ofthird portion 118 in the axial direction.First end 120 ofthird portion 118 may be attached tosecond end 106 offirst portion 102.First end 120 ofthird portion 118 may be attached tosecond end 106 offirst portion 102 by an adhesive, including any adhesive disclosed herein. The orientation of the attachment may be the same as any way thesecond portion 109 could be attached tofirst portion 102. The first non-human-derived fiber may be the same type of fiber as the second non-human-derived fiber. In other embodiments, the first non-human-derived fiber may be different from the second non-human-derived fiber. The second non-human-derived fiber may be added to provide a longer length to the thread. The thread may be used for orthoscopic applications. The thread may often involve tying knots on the outside of the wound or the human body, and a longer thread may allow for knots to be more easily tied and manipulated. -
Thread 116 may have 4 to 8 lbs of ultimate tensile strength. The strength of the thread may be limited by the fascia fiber and may be related to the diameter of the fascia fiber. When force is applied, the thread may break at the fascia fiber and not the junction of the fascia fiber with the non-human-derived fiber. In other words, the adhesive may have a higher ultimate tensile strength than the fascia fiber. -
Second portion 109 ofthread 100 may contact a piercingelement 122. Piercingelement 122 may be a surgical needle, other needle, or any suitable device.Second portion 109 may be fastened to piercingelement 122. In embodiments, one end of piercingelement 122 may be crimped ontosecond portion 109, an adhesive may attach piercingelement 122 tosecond portion 109,second portion 109 may be tied onto piercingelement 122, orsecond portion 109 may be attached to piercingelement 122 by other fastening means. Piercingelement 122 may not be considered part ofthread 100. -
Thread 116 may have a length based on the intended medical or surgical procedure. The thread may be long enough so that a knot may be tied, and a medical professional may not need to use magnifying glasses tie the knot. The total length ofthread 116 may be from 18 inches to 54 inches, 15 inches to 18 inches, 18 inches to 24 inches, 24 inches to 30 inches, 30 inches to 36 inches, 36 inches to 40 inches, 40 inches to 48 inches, 48 inches to 54 inches, over 48 inches, or any combination of ranges according to embodiments. The total length ofthread 116 does not include piercingelement 122. -
First portion 102 may have a length from 6 inches to 8 inches, from 8 inches to 10 inches, from 10 inches to 12 inches, from 12 inches to 18 inches, over 18 inches, or any combination of ranges according to embodiments.First portion 102 may have a diameter from 300 μm to 400 μm, 250 μm to 300 μm, 300 μm to 350 μm, 350 μm to 400 μm, 400 μm to 450 μm, over 450 μm, or any combination of ranges according to embodiments.Thread 100 may have a maximum diameter that does not exceed the diameter of the first portion by greater than 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, or 60 μm in embodiments. The maximum diameter of the thread may be where the first portion attaches to the second portion of third portion. -
Second portion 109 may have a length from 6 inches to 8 inches, from 8 inches to 10 inches, from 10 inches to 12 inches, from 12 inches to 18 inches, 18 inches to 24 inches, over 24 inches, or any combination of ranges according to embodiments. Becausesecond portion 109 may be non-human-derived fiber,second portion 109 may not be limited in length, and the length may be based on commercially available fibers. The length ofthird portion 118 may be equal to, within 5% of, within 10% of, or within 20% of the length ofsecond portion 109. - As shown in
FIG. 2 , embodiments may include amethod 200 of forming a thread. The thread may be any thread described herein.Method 200 may include obtaining and forming the fascia fiber. A fascia fiber may be obtained according to U.S. Patent Application U.S. Patent Application No. 61/779,269 filed Mar. 13, 2013 or Ser. No. 14/204,346 filed Mar. 11, 2015, the contents of which are incorporated herein by reference for all purposes. For example, in some embodiments, a method of obtaining a fascia fiber may include obtaining a deceased donor fascia tissue, treating the deceased donor fascia tissue with acetone, and obtaining one or more intact fascia fibers from the treated deceased donor fascia tissue. An intact fascia fiber may have a diameter within a range from 5 to 200 microns. In some cases, an intact fascia fiber may have a length greater than 20 cm. The intact fascia fiber may be used directly as a fascia fiber, or the intact fascia fiber may be further processed (e.g. cut into two or more pieces) to produce a fascia fiber. - At
block 202,method 200 may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber. Attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber may include directly binding the section at the limit of the fascia fiber in the axial direction with the section at the limit of the first non-human-derived fiber in the axial direction. For example,FIG. 3A shows an axial cross sectional view offascia fiber 302 attached to non-human-derivedfiber 304. For the insertion, non-human-derivedfiber 304 may have a large diameter thanfascia fiber 302 across the whole of non-human-derivedfiber 304, or non-human-derivedfiber 304 may have a larger diameter at only end 306. - In some embodiments,
method 200 may include tapering the fascia fiber to form the first end of the fascia fiber before attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber. For example,FIG. 3B shows an axial cross sectional view offascia fiber 308 and non-human-derivedfiber 310. Tapering is shown inarea 312.Fascia fiber 308 may be tapered at one end and from one side. Independently, non-human-derivedfiber 310 may be tapered at one end and from one side. In embodiments, non-human-derivedfiber 310 may not be tapered while fascia fiber may be tapered. Non-human-derivedfiber 310 may be a woven fiber, which may be more difficult to taper. The tapered ends decrease the thickness of the fibers and may reduce the diameter or reduce the diameter of the thread at the junction. Avoiding increasing the diameter of the thread at the junction may be desirable for surgical applications. A smaller diameter at the junction avoids unnecessarily enlarging suture points in a patient, which may then result in faster recovery times. The first end of the fascia fiber may be attached to the first end of the first non-human-derived fiber by any adhesive described herein. - In some embodiments,
method 200 may include a tubular component that may bind the fascia fiber to the non-human-derived fiber. The ends of the fibers may be inserted into the tubular component, which may be a tube, cylinder, or other similar shape. For example,FIG. 3C shows an axial cross sectional view offascia fiber 314 and non-human-derivedfiber 316. One end offascia fiber 314 and one end of non-human-derivedfiber 316 may be inserted intotube 318.Tube 318 may be reduced in size to bind the two fibers together. Before reduction in size,tube 318 may be 0.5 inches to 2 inches long, including 0.5 inches to 1 inch, 1 inch to 1.5 inches, or 1.5 inches to 2 inches. The inner diameter oftube 318 before reduction in size may be slightly larger than the diameter of the fascia fiber or the non-human-derived fiber. The thickness of the wall oftube 318 may be from 100 μm to 600 μm. - The microtube may include tubing made of acrylated olefins, polyvinylidene fluoride (e.g, Kynar®), polyvinylchloride, cellulose, polyolefins (e.g., Neoprene), polytetrafluoroethylene (e.g., Teflon®), fluoropolymer elastomer (e.g., Viton®), or other suitable material. In some embodiments,
tube 318 may be heated, which may causetube 318 to shrink and bind the fibers together. In these embodiments,tube 318 may be a material, such as those previously listed, that shrinks under application of heat. These materials are sometimes known as heat shrink tubing. Heat may be applied to the tubular component by conduction, convection, or radiation. A heat gun, heat fan (e.g., a device resembling a hair dryer), iron, heated surface, or other suitable device may be used to shrink the tubular material. Another method to reduce the size oftube 318 may be the application of a chemical that causestube 318 to shrink. For example, cellulose tubing may shrink after water is applied. When a tubular component is used, the binding of the fibers may be solely a mechanical binding. Adhesive may be excluded to avoid difficulties or inefficiencies in applying to small fibers. However, applying an adhesive to attach fibers may be faster than using a tubular component, which requires inserting the fibers into a tubular component and then heating or otherwise treating the tubular component. In some embodiments, adhesive may be used in combination with the tubular component to additionally increase binding strength. For example, an adhesive may first be applied to two ends of fibers, and the tube may be shrunk on top of the two ends. In other embodiments, adhesive may be applied to the inner surface of the tube, and heat may be applied to shrink the tube and/or cure the adhesive. In these and other embodiments, the fascia fibers may be tapered before inserting the fascia fiber and non-human-derived fiber into a tubular component. - At
block 204,method 200 may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.Method 200 may include tapering the fascia fiber to form the second end of the fascia fiber before attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber. Attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber may be in a manner similar to any described herein for the attaching of the first end of the fascia fiber to the first end of the first non-human-derived fiber. - In some embodiments,
method 200 may include determining the length of the fascia fiber to be used before attaching the fascia fiber to either non-human-derived fiber. Determining the length of the fascia fiber may include obtaining the length of a wound or surgical incision to be closed and calculating a length of the fascia fiber needed for the length of the wound or surgical incision. The length of the fascia fiber may be selected based on the length of the wound or surgical incision. The fascia fiber may be cut to the determined length. Threads may be manufactured to different lengths of fascia fiber to increase the amount of fascia fiber used and reduce the amount of fascia fiber wasted. For example, a long piece of fascia fiber may be divided into two smaller portions that may both be utilized for different applications instead of using the long piece for one application requiring a shorter fascia fiber. - In some embodiments,
method 200 may include determining the length of at least one of the first non-human-derived fiber or the second non-human-derived fiber. The length of the non-human-derived fibers may be a length based on the preference of the medical professional (e.g. a surgeon who is applying thread to a patient) or a length suitable to allow the thread to be tied off. - As shown in
FIG. 4 , embodiments may include amethod 400 of suturing. Suturing may be used to close a wound or a surgical incision in a tissue of a human or animal subject. - At
block 402,method 400 may include inserting a thread into a soft tissue. The soft tissue may include the skin of a human patient. The thread may include a first portion including a fascia fiber and a second portion including a non-human-derived fiber. The first portion may include any portion of the fascia fiber described herein, and the second portion may be any portion of the non-human-derived fiber described herein. Inserting the thread into the soft tissue may include inserting the second portion into the soft tissue before the first portion. Inserting the non-human-derived fiber may provide the medical professional similar tactile feedback and resistance as with conventional non-human-derived fibers for suturing. The second portion may be in contact with a piercing element.Method 400 may include attaching the second portion to the piercing element, andmethod 400 may include inserting the piercing element into the soft tissue before inserting the thread into the soft tissue. -
Method 400 may include a thread that includes a third portion comprising a second non-human-derived fiber. The third portion may be any portion of the second non-human-derived fiber described herein. The first portion may be attached to the second portion, and the first portion may be attached to the third portion. Inserting the thread into the soft tissue, as inblock 402, may exclude inserting the third portion into the soft tissue. - At
block 404,method 400 may include removing the second portion from the first portion when the first portion is in contact with the soft tissue.Method 400 may also include removing the third portion from the first portion when the first portion is in contact with the soft tissue. Removing the second portion or the third portion may be by using scissors or a knife edge. Removing the portions may include removing adhesive used to attach either portion to the first portion of fascia fiber. - At
block 406,method 400 may include fastening the first portion to the soft tissue. In some embodiments, fastening the first portion to the soft tissue may occur before removing the second portion from the first portion.Method 400 may include tying the first portion in a surgical knot to fasten the first portion to the soft tissue. Tying the first portion may include closing a wound or a surgical incision. - The soft tissue may not have an immunoresponse to the first portion. The first portion may be hypoallergenic
-
FIG. 5A is a simplified illustration of suturing. Asoft tissue 502 and asoft tissue 504 are shown as being at least partially separated by some space or otherwise as being at least partially unconnected from one another.Soft tissue 502 andsoft tissue 504 may be human dermal layers and may be separated by an incision, such as by a scalpel or other cutting instrument. In some examples,soft tissue 502 andsoft tissue 504 may have been separated as a result of some unintended trauma to the soft tissue.Soft tissue 502 andsoft tissue 504 may be connected to a common section (not shown) of soft tissue. - The thread used to suture
soft tissue 502 andsoft tissue 504 together may include aportion 506 of native fiber, such as fascia fiber.Portion 506 may be attached at one end to afirst portion 508 of non-human-derived fiber and attached at the other end to asecond portion 510 of non-human-derived fiber.First portion 508 of non-human-derived fiber may be attached toneedle 512 or any other piercing element. The attachment offirst portion 508 toneedle 512 may be by a fastening device, orfirst portion 508 may be threaded throughneedle 512.Portion 506 may be any portion of fascia fiber described herein.First portion 508 of non-human-derived fiber andsecond portion 510 of non-human-derived fiber may be any portion of non-human-derived fiber described herein. -
Needle 512 may pierce throughsoft tissue 502 andsoft tissue 504 several times, drawing the thread withneedle 512. InFIG. 5A , sections ofportion 506 of native fiber that are behind eithersoft tissue 502 orsoft tissue 504 are depicted as dashed lines. Suturing may include alternating piercing ofsoft tissue 502 andsoft tissue 504.First portion 508 is completely pulled through either or both ofsoft tissue 502 orsoft tissue 504.Second portion 510 may not enter either or both ofsoft tissue 502 orsoft tissue 504. In other words,second portion 510 may not a cross section with its circumference surrounded by soft tissue.Second portion 510 may not contact soft tissue or may contact soft tissue only on the planar or near-planar surface of the soft tissue. - The thread may be manipulated such that
portion 506 pullssoft tissue 502 andsoft tissue 504 together. The effect of bringingsoft tissue 502 andsoft tissue 504 may be to close a wound or a surgical incision.Portion 506 of native fiber of the thread may be tied off using a surgical knot or any suitable suturing technique.First portion 508 of non-human-derived fiber andsecond portion 510 of non-human-derived fiber may be removed from the native fiber. Removal may be by scissors, a razor, a knife-edge, or by an applied force (e.g., pulling thread apart at the attached connection). In some cases, removal of the non-human-derived fiber may also include removal of a section of the native fiber. -
FIG. 5B illustrates a possible configuration after removal offirst portion 508 andsecond portion 510.Soft tissue 502 andsoft tissue 504 are in contact.Portion 506 of native fiber may provide a force to maintain contact between the two soft tissues. Areas whereportion 506 are behind the soft tissue are illustrated as dashed lines. Because the native fiber is completely natural, the likelihood of the soft tissue suffering an immunoresponse is low. Human-derived fibers may be absorbed or remodeled (i.e., bio-resorbed and replaced by the patient's own tissue) in the human body. -
FIG. 6 is a photo of an example thread.Uncoiled portion 602 is fascia fiber, andcoiled portion 604 is non-human-derived fiber. The fascia fiber is 12 to 18 inches long, and the non-human-derived fiber is 18 inches long. The non-human-derived fibers is Teleflex® Force Fiber® #2, which is a polyethylene fiber. - Nine fascia fibers 12 to 18 inches long are obtained. The fascia fibers are tapered at both ends to reduce the diameter of the fiber at the end. Each of the fascia fibers are separately attached at one end to one end of a non-human-derived fiber of nylon, polyester, polyethylene, polygycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, or silk to form 9 separate threads. The non-human-derived fiber is about 18 inches long. The fascia fibers are attached to the non-human-derived fiber by cyanoacrylate adhesive. Each of the fascia fibers at the other end is then attached to the same type of non-human-derived fiber to form 9 separate threads with fascia fiber attached at both ends to separate non-human-derived fibers of the same type. The second non-human-derived fiber is about 18 inches long. The fascia fiber is attached to the second non-human-derived fiber by cyanoacrylate adhesive.
- Nine fascia fibers 12 to 18 inches long are obtained. One end of each fascia fibers is inserted into a separate tube about 1 inch in length. One end of a non-human-derived fiber of nylon, polyester, polyethylene, polygycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, and silk is each inserted into a separate tube. The separate tubes have an inner diameter slightly larger than the diameter of the fascia fiber and the non-human-derived fiber. The tube is heated to shrink the tube to bind the fascia fiber with the non-human-derived fiber. The non-human-derived fiber is about 18 inches long. The process of binding the fascia fiber with the non-human-derived fiber with a tube is repeated with the other end of the fascia fiber to a second non-human-derived fiber of the same type. The second non-human-derived fiber is about 18 inches long. Nine separate threads with fascia fiber attached at both ends to separate non-human-derived fibers of the same type are formed.
- Example 3 is repeated except that the fascia fibers are tapered at both ends before the fibers are inserted into the tube.
- Example 3 is repeated except that the fascia fibers are attached to the non-human-derived fibers with cyanoacrylate before shrinking the tube with applied heat.
- Example 4 is repeated except that the fascia fibers are attached to the non-human-derived fibers with cyanoacrylate before shrinking the tube with applied heat.
- Each of the threads of Examples 3, 4, 5, and 6 is attached to a surgical needle. Each thread is used for suturing. A knot is tied in each thread to close a wound or surgical incision in a patient. The non-human-derived fibers are then cut off the thread, leaving only fascia fiber in contact with the patient.
- In a first aspect, embodiments may include a thread for suturing. The thread may include a first portion that includes a fascia fiber. The first portion may have a first end that includes the fascia fiber. The thread may also include a second portion that includes a non-human-derived fiber. The second portion may have a first end that includes the non-human-derived fiber. The first end of the second portion may be attached to the first end of the first portion.
- In embodiments, the non-human-derived fiber may be a first non-human-derived fiber. The thread may further include a third portion that includes a second non-human-derived fiber. The first portion may have a second end that includes the fascia fiber. The third portion may have a first end that includes the second non-human-derived fiber. The first end of the third portion may be attached to the second end of the first portion. The first non-human-derived fiber and the second non-human-derived fiber may be the same type of fiber.
- The thread may have a total length from 36 inches to 54 inches. The first portion may have a length from 12 inches to 18 inches. The second portion may have a length from 12 inches to 18 inches.
- The first end of the second portion may be attached to the first end of the first portion by an adhesive. The adhesive may include a cyanoacrylate or a cyanoacrylate ester.
- The thread may have a strength that allows the thread to be used as a surgical suture.
- The first portion may have a diameter from 300 μm to 400 μm. The thread may have a maximum diameter that does not exceed the diameter of the first portion by greater than 50 μm.
- In embodiments, the thread may further include a piercing element in contact with the second portion. The piercing element may be a surgical needle.
- The fascia fiber may be obtained from a single cadaveric donor. The non-human-derived fiber may include nylon, polyester, polyethylene, polyglycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, or silk.
- In a second aspect, embodiments may include methods of forming a thread. The methods may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber. The methods may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.
- In embodiments, methods may include tapering the fascia fiber to form the first end of the fascia fiber before attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber. Methods may also include tapering the fascia fiber to form the second end of the fascia fiber before attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber.
- In embodiments, attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber may include applying an adhesive to at least one of the first end of the fascia fiber or the first end of the first non-human-derived fiber, and attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber comprises applying the adhesive to at least one of the second end of the fascia fiber or the first end of the second non-human-derived fiber. The adhesive may include a cyanoacrylate or a cyanoacrylate ester.
- In these and other embodiments, attaching the first end of the fascia fiber to the first end of the first non-human-derived fiber may include inserting the first end of the fascia fiber into a first end of a first tubular component, inserting the first end of the first non-human-derived fiber into a second end of the first tubular component, where the second end is on an opposite end of the first tubular component as the first end of the first tubular component, and reducing an inner diameter of the first tubular component.
- In embodiments, attaching the second end of the fascia fiber to the first end of the second non-human-derived fiber may include inserting the second end of the fascia fiber into a first end of a second tubular component, inserting the first end of the second non-human-derived fiber into a second end of the second tubular component, where the second end is on an opposite end of the second tubular component as the first end of the second tubular component, and reducing an inner diameter of the second tubular component.
- Reducing the inner diameter of the first tubular component may include heating the first tubular component. In some embodiments, reducing the inner diameter of the first tubular component comprises applying water to the first tubular component.
- Methods may include forming the fascia fiber. The fascia fiber may be obtained from a single cadaveric donor.
- Embodiments may include attaching a second end of the first non-human-derived fiber to a piercing element. In other embodiments, methods may include attaching a second end of the second non-human-derived fiber to a piercing element. The piercing element may be a surgical needle.
- The first non-human-derived fiber and the second non-human-derived fiber may be the same type of fiber.
- The thread may have a total length from 36 inches to 54 inches. The fascia fiber may have a length from 12 inches to 18 inches. The first non-human-derived fiber may have a length from 12 inches to 18 inches. The second non-human-derived fiber may have a length from 12 inches to 18 inches. The fascia fiber may have a diameter from 300 μm to 400 μm. The thread may have a maximum diameter that does not exceed the diameter of the fascia fiber by greater than 50 μm.
- The first non-human-derived fiber or the second non-human-derived fiber may include nylon, polyester, polyethylene, polyglycolic acid, polylactic acid, polyvinylidene fluoride, polypropylene, catgut, or silk.
- The thread formed may be any embodiment of a thread described herein.
- In a third aspect, embodiments may include methods of suturing. The methods may include inserting a thread into a soft tissue. The thread may include a first portion that includes a fascia fiber and a second portion that includes a non-human-derived fiber. Inserting the thread into the soft tissue may include inserting the second portion into the soft tissue before the first portion. The methods may further include removing the second portion from the first portion when the first portion is in contact with the soft tissue.
- In embodiments, the methods may include a thread that includes a third portion of a second non-human-derived fiber. The first portion may be attached to the second portion, and the first portion may be attached to the third portion. Inserting the thread into the soft tissue may not include inserting the third portion into the soft tissue. The methods may further include removing the third portion from the first portion when the first portion is in contact with the soft tissue. The soft tissue may be skin of a human patient.
- In embodiments, the second portion of the thread may be in contact with a piercing element. Methods may also include inserting the piercing element into the soft tissue before inserting the thread into the soft tissue.
- Methods may include fastening the first portion to the soft tissue. Embodiments may include tying the first portion to fasten the first portion to the soft tissue. Tying the first portion may include closing a wound or a surgical incision.
- The soft tissue may not have an immunoresponse to the first portion. The thread may be any thread described herein.
- All patents, patent publications, patent applications, journal articles, books, technical references, and the like discussed in the instant disclosure are incorporated herein by reference in their entirety for all purposes.
- In the preceding description, for the purposes of explanation, numerous details have been set forth in order to provide an understanding of various embodiments of the present technology. It will be apparent to one skilled in the art, however, that certain embodiments may be practiced without some of these details, or with additional details.
- Having described several embodiments, it will be recognized by those of skill in the art that various modifications, alternative constructions, and equivalents may be used without departing from the spirit of the invention. Additionally, a number of well-known processes and elements have not been described in order to avoid unnecessarily obscuring the present invention. Additionally, details of any specific embodiment may not always be present in variations of that embodiment or may be added to other embodiments.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither, or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included.
- As used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a method” includes a plurality of such methods and reference to “the tissue” includes reference to one or more tissues and equivalents thereof known to those skilled in the art, and so forth. The invention has now been described in detail for the purposes of clarity and understanding. However, it will be appreciated that certain changes and modifications may be practice within the scope of the appended claims.
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/876,809 US10772986B2 (en) | 2017-01-26 | 2018-01-22 | Fascia fibrous compositions and methods for their use and manufacture |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762450957P | 2017-01-26 | 2017-01-26 | |
US15/876,809 US10772986B2 (en) | 2017-01-26 | 2018-01-22 | Fascia fibrous compositions and methods for their use and manufacture |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180207314A1 true US20180207314A1 (en) | 2018-07-26 |
US10772986B2 US10772986B2 (en) | 2020-09-15 |
Family
ID=62905548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/876,809 Active 2038-12-15 US10772986B2 (en) | 2017-01-26 | 2018-01-22 | Fascia fibrous compositions and methods for their use and manufacture |
Country Status (1)
Country | Link |
---|---|
US (1) | US10772986B2 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2591063A (en) * | 1949-05-14 | 1952-04-01 | Goldberg Harry | Surgical suture |
US4894063A (en) * | 1983-05-24 | 1990-01-16 | Baxter International Inc. | Barrier layer for implantable tendons and ligaments |
US20040267362A1 (en) * | 2003-06-30 | 2004-12-30 | Julia Hwang | Scaffold for connective tissue repair |
US20090054911A1 (en) * | 2006-12-04 | 2009-02-26 | Gregory Mueller | Surgical threading device and method for using same |
US20090248070A1 (en) * | 2008-04-01 | 2009-10-01 | Kosa Timothy D | Anchoring Suture |
US7875063B1 (en) * | 1991-05-13 | 2011-01-25 | Tyco Healthcare Group Lp | Tissue repair device and apparatus and method for fabricating same |
US20120109193A1 (en) * | 2010-10-28 | 2012-05-03 | Tyco Healthcare Group Lp | Modular Suture |
US20140271790A1 (en) * | 2013-03-13 | 2014-09-18 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
US20170055983A1 (en) * | 2014-05-07 | 2017-03-02 | Parcus Medical, Llc | Multipart suture |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361552A (en) | 1980-09-26 | 1982-11-30 | Board Of Regents, The University Of Texas System | Wound dressing |
US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
GB9400163D0 (en) | 1994-01-06 | 1994-03-02 | Geistlich Soehne Ag | Membrane |
US6203755B1 (en) | 1994-03-04 | 2001-03-20 | St. Jude Medical, Inc. | Electron beam sterilization of biological tissues |
US5797871A (en) | 1994-08-19 | 1998-08-25 | Lifenet Research Foundation | Ultrasonic cleaning of allograft bone |
US5556379A (en) | 1994-08-19 | 1996-09-17 | Lifenet Research Foundation | Process for cleaning large bone grafts and bone grafts produced thereby |
US5976104A (en) | 1994-08-19 | 1999-11-02 | Lifenet Research Foundation | Recirculation method for cleaning essentially intact bone grafts using pressure mediated flow of solutions and bone grafts produced thereby |
US5977034A (en) | 1994-08-19 | 1999-11-02 | Lifenet Research Foundation | Composition for cleaning bones |
GB9721585D0 (en) | 1997-10-10 | 1997-12-10 | Geistlich Soehne Ag | Chemical product |
EP0734736A1 (en) | 1995-03-31 | 1996-10-02 | Toyo Boseki Kabushiki Kaisha | Medical device and method for producing the same |
US6024735A (en) | 1996-03-20 | 2000-02-15 | Lifenet Research Foundation | Process and composition for cleaning soft tissue grafts optionally attached to bone and soft tissue and bone grafts produced thereby |
US6189537B1 (en) | 1996-09-06 | 2001-02-20 | Lifenet | Process for producing osteoinductive bone, and osteoinductive bone produced thereby |
US6152142A (en) | 1997-02-28 | 2000-11-28 | Tseng; Scheffer C. G. | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
US5977432A (en) | 1997-06-09 | 1999-11-02 | Life Net Research Foundation | Process for cleaning bone grafts using centrifugal force and bone grafts produced thereby |
US6432710B1 (en) | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
US7662409B2 (en) | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US6837907B2 (en) | 2001-03-28 | 2005-01-04 | Lifenet | Method for debriding bone, and bone debrided thereby |
US7347876B2 (en) | 2001-04-25 | 2008-03-25 | Ray Jui-Fang Tsai | Method for expansion of epithelial stem cells |
AU2002329884A1 (en) | 2001-08-27 | 2003-03-10 | Regeneration Technologies, Inc. | Processed soft tissue for topical or internal application |
TWI290055B (en) | 2002-03-14 | 2007-11-21 | Tissuetech Inc | Amniotic membrane covering for a tissue surface and devices facilitating fastening of membranes |
US20030187515A1 (en) | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
AU2003245470A1 (en) | 2002-06-12 | 2003-12-31 | Boston Scientific Limited | Medical slings |
CN1720055A (en) | 2002-10-04 | 2006-01-11 | 组织技术公司 | Retinal pigment epithelial cell cultures on amniotic membrane and transplantation |
GB2414990B (en) | 2003-02-21 | 2007-05-23 | Uab Research Foundation | Biologically active native biomatrix composition |
WO2005001079A2 (en) | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Soft tissue repair and regeneration using postpartum-derived cells |
WO2005020847A2 (en) | 2003-08-25 | 2005-03-10 | Cook Biotech Incorporated | Graft materials containing bioactive substances, and methods for their manufacture |
CA2548534C (en) | 2003-10-28 | 2014-01-07 | Allosource | Methods for determining microbial contamination of allograft products |
US7393437B2 (en) | 2004-09-14 | 2008-07-01 | The University Of Hong Kong | Photochemically crosslinked collagen scaffolds and methods for their preparation |
CA2602100A1 (en) | 2005-03-16 | 2006-09-28 | Musculoskeletal Transplant Foundation | Soft tissue processing |
US20100112543A1 (en) | 2005-03-16 | 2010-05-06 | Manh-Dan Ngo | Processing soft tissue, methods and compositions related thereto |
AU2006247276A1 (en) | 2005-05-19 | 2006-11-23 | Albiorex, Llc | Terminal sterilization of injectable collagen products |
JP5109030B2 (en) | 2005-07-25 | 2012-12-26 | 茂 木下 | Sheet-like composition |
US8932641B2 (en) | 2005-08-26 | 2015-01-13 | Amnos Co., Ltd. | Dried amnion and method for drying treatment of amnion |
US8153162B2 (en) | 2005-09-27 | 2012-04-10 | Tissuetech, Inc. | Purified amniotic membrane compositions and methods of use |
US8187639B2 (en) | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
US7498041B2 (en) | 2005-10-12 | 2009-03-03 | Lifenet Health | Composition for repair of defects in osseous tissues |
US8158141B2 (en) | 2005-11-09 | 2012-04-17 | Paul Hong-Dze Chen | Cell transplant device for treatment of corneal wound |
US9107982B2 (en) | 2005-11-09 | 2015-08-18 | Paul Hong-Dze Chen | Cultured tissue transplant device |
ES2628129T3 (en) | 2005-12-28 | 2017-08-01 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using postpartum derived cells |
US8168215B2 (en) | 2006-06-16 | 2012-05-01 | Fmc Biopolymer As | Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof |
US8105634B2 (en) | 2006-08-15 | 2012-01-31 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
US8372437B2 (en) | 2006-08-17 | 2013-02-12 | Mimedx Group, Inc. | Placental tissue grafts |
US20120269774A1 (en) | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
EP2664341A3 (en) | 2006-10-06 | 2014-01-08 | Anthrogenesis Corporation | Native (telopeptide) placental collagen compositions |
US8198245B2 (en) | 2007-07-27 | 2012-06-12 | Humacyte, Inc. | Compositions and methods for soft tissue augmentation |
US20090054339A1 (en) | 2007-08-22 | 2009-02-26 | Marshall Vivienne S | Novel cellular factor-containing solution compositions |
EP3189731B1 (en) | 2007-09-07 | 2020-01-29 | MiMedx Group, Inc. | Placental tissue grafts and improved methods of preparing and using the same |
WO2009042514A1 (en) | 2007-09-25 | 2009-04-02 | Integra Lifesciences Corporation | Flowable wound matrix and its preparation and use |
WO2009046377A2 (en) | 2007-10-04 | 2009-04-09 | Medistem Laboratories, Inc. | Compositions and methods of stem cell therapy for autism |
US9358320B2 (en) | 2008-04-25 | 2016-06-07 | Allosource | Multi-layer tissue patches |
EP2300599B1 (en) | 2008-06-09 | 2017-03-01 | Targazyme, Inc. | Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase |
KR20100054711A (en) | 2008-11-14 | 2010-05-25 | 메디포스트(주) | Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases |
US9192695B2 (en) | 2008-11-20 | 2015-11-24 | Allosource | Allografts combined with tissue derived stem cells for bone healing |
GB0903810D0 (en) | 2009-03-05 | 2009-04-22 | Regentec Ltd | Delivery system |
EP2414511B1 (en) | 2009-03-31 | 2017-07-26 | The Board of Regents of The University of Texas System | Isolation of human umbilical cord blood-derived mesenchymal stem cells |
US8541233B2 (en) | 2009-06-26 | 2013-09-24 | Lifenet Health | Methods for collecting and processing autografts, processed autografts, kits for collecting and transporting autografts, and tools for preparing autografts |
EP2470231B1 (en) | 2009-08-25 | 2019-10-09 | Tissue Tech, Inc. | Umbilical cord amniotic membrane products |
EP2806023B1 (en) | 2009-11-30 | 2015-09-23 | Pluristem Ltd. | Adherent cells from placenta and use of same in disease treatment |
CA2782815A1 (en) | 2009-12-17 | 2011-06-23 | Queen's University At Kingston | Decellularized adipose tissue |
ES2663720T3 (en) | 2010-02-18 | 2018-04-16 | Osiris Therapeutics, Inc. | Methods of manufacturing therapeutic products comprising vitalized placental dispersions |
AU2011249406B2 (en) | 2010-05-06 | 2015-05-14 | Stem Cell Medicine Ltd. | Stem cell bank for personalized medicine |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8475827B2 (en) | 2010-07-06 | 2013-07-02 | Cryolife, Inc. | Tissue implants for implantation and methods for preparing the same |
US20120009644A1 (en) | 2010-07-06 | 2012-01-12 | Cryolife, Inc. | Tissue Implants for Implantation and Methods for Preparing the Same |
US8377143B2 (en) | 2010-07-06 | 2013-02-19 | Cryolife, Inc. | Tissue implants for implantation and methods for preparing the same |
KR20230005417A (en) | 2010-12-17 | 2023-01-09 | 셀룰래리티 인코포레이티드 | Treatment of immune-related diseases and disorders using amnion derived adherent cells |
US20120201787A1 (en) | 2010-12-17 | 2012-08-09 | Abbot Stewart | Treatment of spinal cord injury and traumatic brain injury using amnion derived adherent cells |
US9433490B2 (en) | 2010-12-22 | 2016-09-06 | University Of Florida Research Foundation, Inc. | Multilayered implant materials derived from amniotic membrane, methods of making the multilayered implant materials, and method of using multilayered implant materials |
DE102011008604A1 (en) | 2011-01-14 | 2012-07-19 | Tutogen Medical Gmbh | Preparation of a graft of animal dermis with sodium sulfide solution |
US20120189586A1 (en) | 2011-01-21 | 2012-07-26 | Carl Randall Harrell | Human Placental Derived Extracellular Matrix and Uses Therof |
WO2012112441A1 (en) | 2011-02-14 | 2012-08-23 | Mimedx Group Inc. | Laminated tissue grafts composed of wharton's jelly and methods of making and using the same |
KR102118457B1 (en) | 2011-02-14 | 2020-06-03 | 미메딕스 그룹 인크. | Tissue grafts modified with a cross-linking agent and methods of making and using the same |
AU2012217975B2 (en) | 2011-02-14 | 2015-11-19 | Mimedx Group Inc. | Micronized placental tissue compositions and methods for making and using the same |
KR102331661B1 (en) | 2011-02-14 | 2021-11-25 | 미메딕스 그룹 인크. | Micronized placental tissue compositions and methods for making and using the same |
WO2012116372A1 (en) | 2011-02-25 | 2012-08-30 | Rosen Richard A | Biomaterials for soft and hard tissue repair |
EP2508212A1 (en) | 2011-04-05 | 2012-10-10 | Universitätsklinikum Freiburg | Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support |
US9017711B2 (en) | 2011-04-28 | 2015-04-28 | Warsaw Orthopedic, Inc. | Soft tissue wrap |
US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
AU2012262311B2 (en) | 2011-05-31 | 2016-04-28 | Lifecell Corporation | Adipose tissue matrices |
ES2822301T3 (en) | 2011-06-10 | 2021-04-30 | Tissuetech Inc | Fetal Support Tissue Processing Methods |
WO2013032938A1 (en) | 2011-08-26 | 2013-03-07 | Tissuetech, Inc. | Methods of sterilizing fetal support tissues |
US20140017280A1 (en) | 2011-10-06 | 2014-01-16 | Mimedx Group, Inc. | Micronized compositions composed of bone grafts and methods of making and using the same |
US8920511B2 (en) | 2011-11-17 | 2014-12-30 | Allosource | Multi-piece machine graft systems and methods |
US20130218274A1 (en) | 2011-12-02 | 2013-08-22 | Mimedx Group, Inc. | Shredded tissue grafts and methods for making and using the same |
US9186382B2 (en) | 2011-12-02 | 2015-11-17 | Mimedx Group, Inc. | Placental tissue grafts produced by chemical dehydration/freeze-drying and methods for making and using the same |
EP2793745B1 (en) | 2011-12-22 | 2019-07-31 | MIMEDX Group Inc. | Cross-linked dehydrated placental tissue grafts and methods for making and using the same |
US9943551B2 (en) | 2012-08-15 | 2018-04-17 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
US11338063B2 (en) | 2012-08-15 | 2022-05-24 | Mimedx Group, Inc. | Placental tissue grafts modified with a cross-linking agent and methods of making and using the same |
US8904664B2 (en) | 2012-08-15 | 2014-12-09 | Mimedx Group, Inc. | Dehydration device and methods for drying biological materials |
US20140106447A1 (en) | 2012-10-12 | 2014-04-17 | Mimedx Group, Inc. | Compositions and methods for recruiting stem cells |
US9180145B2 (en) | 2012-10-12 | 2015-11-10 | Mimedx Group, Inc. | Compositions and methods for recruiting and localizing stem cells |
US20150140114A1 (en) | 2013-11-19 | 2015-05-21 | John R. SASKO | Skin treatment protocol utilizing amniotic solution |
-
2018
- 2018-01-22 US US15/876,809 patent/US10772986B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2591063A (en) * | 1949-05-14 | 1952-04-01 | Goldberg Harry | Surgical suture |
US4894063A (en) * | 1983-05-24 | 1990-01-16 | Baxter International Inc. | Barrier layer for implantable tendons and ligaments |
US7875063B1 (en) * | 1991-05-13 | 2011-01-25 | Tyco Healthcare Group Lp | Tissue repair device and apparatus and method for fabricating same |
US20040267362A1 (en) * | 2003-06-30 | 2004-12-30 | Julia Hwang | Scaffold for connective tissue repair |
US20090054911A1 (en) * | 2006-12-04 | 2009-02-26 | Gregory Mueller | Surgical threading device and method for using same |
US20090248070A1 (en) * | 2008-04-01 | 2009-10-01 | Kosa Timothy D | Anchoring Suture |
US20120109193A1 (en) * | 2010-10-28 | 2012-05-03 | Tyco Healthcare Group Lp | Modular Suture |
US20140271790A1 (en) * | 2013-03-13 | 2014-09-18 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
US20170055983A1 (en) * | 2014-05-07 | 2017-03-02 | Parcus Medical, Llc | Multipart suture |
Also Published As
Publication number | Publication date |
---|---|
US10772986B2 (en) | 2020-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5733535B2 (en) | Flocking anchor and system and method using the same | |
US10010317B2 (en) | Method of improving elasticity of tissue of living body | |
US20020019670A1 (en) | Implantable tissue augmentation device | |
JP2019193835A (en) | Balloon catheter suture system having pledget, method, and device | |
JP7377248B2 (en) | Connectors and wraps for nerve end-to-side anastomoses | |
JP2005503850A (en) | Soft and calcified tissue implant | |
JP6832944B2 (en) | Implant device with preset pulley system | |
US9186241B2 (en) | Graft fixation device | |
US20140288594A1 (en) | Dual Diameter, Dual Density ePTFE Suture | |
JP5870473B2 (en) | Bone graft suture | |
US10772986B2 (en) | Fascia fibrous compositions and methods for their use and manufacture | |
WO2006073398A1 (en) | Soft tissue suspension device | |
US10470872B1 (en) | Implantable articles for attaching tendons and/or ligaments to bone and/or cartilage, assemblies thereof, and methods of use thereof | |
Melvin et al. | A durable load bearing muscle to prosthetic coupling | |
CA3033922C (en) | A clip and a system for ligament reconstruction | |
RU2234868C2 (en) | Surgical suture material | |
US20130110134A1 (en) | Shapeable passer for surgical cable or suture | |
JPH0956720A (en) | Medical strait suturing needle with loop suture | |
Gilman et al. | Experimental study of the fusion of the mitral annulus at the site of polar cross plication in dogs | |
WO2008125225A1 (en) | Vessel connector and kit having an applicator for surgery | |
JP2013046716A (en) | Spacer fixing tool and spacer with the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: ALLOSOURCE, COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAMANIEGO, ADRIAN C.;ROMANSKY, TERESA C.;SOUTHARD, MATTHEW J.;SIGNING DATES FROM 20180808 TO 20181029;REEL/FRAME:047698/0730 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |